Document Detail


Adaptive Immune Responses and HER2/neu Positive Breast Cancer.
MedLine Citation:
PMID:  23420038     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Oncogenic signaling, such as HER2/neu signaling, has been shown to play major role for tumorigenesis in a subset of breast cancer patients. The use of anti-HER2/neu antibody has not only revealed the mechanisms for HER2/neu signaling but also shown a therapeutic advantage of its blockade. Indeed, the use of trastuzumab has greatly improved the treatment of HER2-positive breast cancer. Although this therapy has been used in the clinic for over twenty years, recent data is still uncovering new mechanisms by which this antibody exerts its anti-tumor activity. In addition to an improved understanding of the molecular mechanisms by which this therapy inhibits growth of tumor cells, the discovery that anti-HE2/neu therapy initiates and requires the adaptive immune system is one of these new mechanisms. The presence of anti-HER2/neu initiated adaptive immunity gives credence to efforts targeted at stimulating the immune system in treating HER2 positive breast cancer. This review focuses on the role of the inflammatory response in HER2 positive breast cancer with particular emphasis on trastuzumab therapy.
Authors:
Eric D Mortenson; Yang-Xin Fu
Related Documents :
18282348 - A case of respiratory akathisia in a cancer patient: a case report.
24367138 - Evaluation of molecular species of prostate-specific antigen complexed with immunoglobu...
2730268 - Bilateral vocal cord paralysis with respiratory failure. a presenting manifestation of ...
8497418 - Vena cava filters: a nursing perspective.
20133238 - Synchronous gastric adenocarcinoma and pancreatic ductal adenocarcinoma.
19038028 - Reliable microrna profiling in routinely processed formalin-fixed paraffin-embedded bre...
Publication Detail:
Type:  JOURNAL ARTICLE    
Journal Detail:
Title:  Current pathobiology reports     Volume:  1     ISSN:  2167-485X     ISO Abbreviation:  Curr Pathobiol Rep     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-2-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101599032     Medline TA:  Curr Pathobiol Rep     Country:  -    
Other Details:
Languages:  ENG     Pagination:  37-42     Citation Subset:  -    
Affiliation:
Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impurity induced non-bulk stacking in chemically exfoliated h-BN nanosheets.
Next Document:  Upexpression of Beclin-1-Dependent Autophagy Protects Against Beta-amyloid-Induced Cell Injury in PC...